Home > Annual Financials > SAMRAT PHARMACHEM

SAMRAT PHARMACHEM Financial Statement Analysis
[BOM: 530125]

The Revenues of SAMRAT PHARMACHEM have decreased by -9.36% YoY .
The Earnings Per Share (EPS) of SAMRAT PHARMACHEM has decreased by -87.00 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

SAMRAT PHARMACHEM Last 5 Annual Financial Results
[BOM: 530125]

StandaloneMar2024
Mar2023
Mar2022
Mar2021
Mar2020
Revenues ₹282 Cr₹311 Cr₹222 Cr₹179 Cr₹137 Cr
Expenses ₹279 Cr₹287 Cr₹198 Cr₹170 Cr₹131 Cr
Operating Profit (Excl OI) ₹2.47 Cr₹24 Cr₹24 Cr₹8.67 Cr₹6.63 Cr
Other Income ₹1.39 Cr₹0.48 Cr₹0.63 Cr₹0.46 Cr₹0.57 Cr
Interest ₹0.69 Cr₹1.23 Cr₹0.68 Cr₹1.28 Cr₹0.98 Cr
Depreciation ₹0.65 Cr₹0.64 Cr₹0.60 Cr₹0.49 Cr₹0.43 Cr
Profit Before Tax ₹2.52 Cr₹23 Cr₹24 Cr₹7.34 Cr₹5.79 Cr
Profit After Tax ₹2.16 Cr₹17 Cr₹17 Cr₹5.33 Cr₹4.24 Cr
Earnings Per Share (Rs)₹7.00₹53.83₹55.62₹17.26₹13.71
PAT Margin (%)0.775.357.752.612.70
ROE(%)3.3830.2544.9519.7719.10
ROCE(%)4.1334.9152.3323.9022.43
Total Debt/Equity(x)0.130.300.160.300.39

Key Financials

Market Cap : ₹ 116.5 Cr
Revenue (TTM) : ₹ 295.4 Cr
Net Profit(TTM) : ₹ 6.5 Cr
EPS (TTM) : ₹ 20.9
P/E (TTM) : 18.0

Industry Peers & Returns1W1M1Y
SAMRAT PHARMACHEM -10.8% -15.4% 9.8%
SUN PHARMACEUTICAL INDUSTRIES 1% 4.6% 47.5%
CIPLA -1.1% -0.3% 20.7%
DR REDDYS LABORATORIES 2.2% 12.1% 21.6%
ZYDUS LIFESCIENCES -2.7% 0.8% 43.8%
DIVIS LABORATORIES 1% -3.2% 59.3%
MANKIND PHARMA 0.8% 12.8% 52.4%
TORRENT PHARMACEUTICALS -1.5% 5.9% 55%
LUPIN 0.9% 7.2% 72.7%


SAMRAT PHARMACHEM Revenues
[BOM: 530125]

Y-o-Y

-9.36 %

5 Yr CAGR

19.64 %

Years Revenues % Change
Mar2024 ₹282 Cr
-9.36
Mar2023 ₹311 Cr
40.09
Mar2022 ₹222 Cr
23.87
Mar2021 ₹179 Cr
30.24
Mar2020 ₹137 Cr -


SAMRAT PHARMACHEM Operating Profit
[BOM: 530125]

Y-o-Y

-89.68 %

5 Yr CAGR

-21.87 %

Years Operating Profit % Change
Mar2024 ₹2.47 Cr
-89.68
Mar2023 ₹24 Cr
-1.28
Mar2022 ₹24 Cr
179.61
Mar2021 ₹8.67 Cr
30.76
Mar2020 ₹6.63 Cr -

Operating Margins
Y-o-Y

-88.57 %

5 Yr CAGR

-34.63 %

Years Operating Margin% % Change
Mar2024 0.88%
-88.57
Mar2023 7.7%
-29.55
Mar2022 10.93%
125.83
Mar2021 4.84%
0.41
Mar2020 4.82% -

SAMRAT PHARMACHEM Profit After Tax
[BOM: 530125]

Y-o-Y

-86.99 %

5 Yr CAGR

-15.47 %

Years Profit After Tax % Change
Mar2024 ₹2.16 Cr
-86.99
Mar2023 ₹17 Cr
-3.22
Mar2022 ₹17 Cr
222.24
Mar2021 ₹5.33 Cr
25.87
Mar2020 ₹4.24 Cr -

PAT Margins
Y-o-Y

-85.61 %

5 Yr CAGR

-26.92 %

Years PAT Margin(%) % Change
Mar2024 0.77 %
-85.61
Mar2023 5.35 %
-30.97
Mar2022 7.75 %
196.93
Mar2021 2.61 %
-3.33
Mar2020 2.7 % -

SAMRAT PHARMACHEM Earnings Per Share (EPS)
[BOM: 530125]

Y-o-Y

-87.00 %

5 Yr CAGR

-15.47 %

Years EPS % Change
Mar2024 ₹7.00
-87.00
Mar2023 ₹54
-3.22
Mar2022 ₹56
222.25
Mar2021 ₹17
25.89
Mar2020 ₹14 -

SAMRAT PHARMACHEM Return on Capital Employed (ROCE)
[BOM: 530125]

Y-o-Y

-88.17 %

5 Yr CAGR

-34.49 %

Years ROCE % Change
Mar2024 4.13%
-88.17
Mar2023 34.91%
-33.29
Mar2022 52.33%
118.95
Mar2021 23.9%
6.55
Mar2020 22.43% -

SAMRAT PHARMACHEM Share Price vs Sensex

Current Share Price : ₹375.7
Current MarketCap: ₹ 116.5 Cr
Updated EOD on :Dec 26,2024

Share Price Returns(%) 1 Week 1 Month 1 Year
SAMRAT PHARMACHEM

-10.8%

-15.4%

9.8%

SENSEX

-2.1%

-2%

11.3%

SAMRAT PHARMACHEM related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about SAMRAT PHARMACHEM Financials


How the annual revenues of SAMRAT PHARMACHEM have changed ?

The Revenues of SAMRAT PHARMACHEM have decreased by -9.36% YoY .

How the Earnings per Share (EPS) of SAMRAT PHARMACHEM have changed?

The Earnings Per Share (EPS) of SAMRAT PHARMACHEM has decreased by -87.00 % YoY .